NCT07241923招募中1 期
A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2070 Injection in Healthy Subjects
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2025年11月15日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Number of Subjects with Adverse Events as Assessed by CTCAE v5.0
研究概览
简要总结
This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study of SYH2070 injection when administered subcutaneously to healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must provide informed consent before the trial, fully understand its content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;
- •Sex: Male or female;
- •Age: 18-60 years (inclusive);
- •Body mass index (BMI) in the range of 19 to 30 kg•m^2 [BMI = weight/height^2 (kg•m^2)] (inclusive), with a weight of no less than 50 kg for males (inclusive) and no less than 45 kg for females (inclusive);
- •Fasting serum TG ≥150 mg/dL (1.7 mmol/L) and ≤ 500 mg/dL (5.6 mmol/L), and LDL-C ≥70 mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L) during the screening and baseline periods;
- •Subjects must maintain stable die, exercise, and other lifestyle habits from 4 weeks prior to screening until the end of the study, with no planned changes to diet, exercise or weight loss programs;
- •Subjects must be able to communicate well with the investigator and can complete the study according to the protocol requirements.
排除标准
- •History of severe allergic diseases or allergic constitution (≥ 3 drug or food allergies), or known history of allergy to the investigational drug components (N-acetylgalactosamine, sodium hydroxide, phosphoric acid) or oligonucleotide drugs;
- •Use of antibody drugs and/or oligonucleotide drugs targeting PCSK9/ANGPTL3/ApoC-III within 12 months prior to screening;
- •Current and/or history of clinically significant medical conditions, including but not limited to circulatory, hematological or hematopoietic, respiratory, endocrine, urinary, digestive system diseases, neurological or psychiatric disorders, infections, tumors, severe trauma, or any other disease that should be excluded or may interfere with the interpretation of the study results, as judged by the investigator;
- •History of major surgery within 6 months prior to screening, or are scheduled to undergo major surgery during the course of the study;
- •History of bariatric surgery within 12 months prior to screening;
- •Have clinically significant abnormalities in vital signs, physical examination, electrocardiogram, and laboratory tests (excluding lipid parameters);
- •Estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m^2 at screening;
- •Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), gamma-glutamyl transferase (GGT), or alkaline phosphatase (ALP) >1.5× upper limit of normal (ULN) at screening (one retest allowed within 1 week);
- •Prolonged QT / QTc interval at screening or baseline (QTcF > 450 ms);
- •Positive result for any of HBsAg, HCV antibody, syphilis antibody, and HIV antibody;
- •Blood loss or donation >200 mL within 3 months prior to screening (excluding menstruation for females), and/or platelet donation within 2 weeks;
- •Use of any drugs, health supplements, vitamins, or dietary supplements known to affect lipid metabolism within the longer of either: (a) 28 days prior to dosing; (b) 7 half-lives of the drug; (3) the duration of the agent's pharmacological effect, including but not limited to statins, fish oil, high-purity omega-3, prescription-dose niacin, fibrates, or anti-estrogen therapy;
研究组 & 干预措施
SYH2070 experimental group
Experimental
Subjects in experimental groups will receive a single subcutaneous injection of SYH2070 injection on Day 1.
干预措施: SYH2070 injection (Drug)
Placebo group
Placebo Comparator
Subjects in placebo groups will receive a single subcutaneous injection of placebo on Day 1.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Subjects with Adverse Events as Assessed by CTCAE v5.0
时间窗: Pre-dose and multiple time points no less than 85 days
次要结局
- The serum TG level after dosing SYH2070 injection(Pre-dose and multiple timepoints no less than 85 days)
- The serum LDL-C level after dosing SYH2070 injection(Pre-dose and multiple timepoints no less than 85 days)
- Plasma Maximum concentration (Cmax)(Pre-dose and multiple timepoints up to 4 days)
- Time to maximum concentration (Tmax)(Pre-dose and multiple timepoints up to 4 days)
- Area under the concentration-time curve from 0 to the collection time t (AUC0-t)(Pre-dose and multiple timepoints up to 4 days)
- Half-Life (t1/2)(Pre-dose and multiple timepoints up to 4 days)
- Area under the concentration-time curve from 0 to infinity (AUC0-∞)(Pre-dose and multiple timepoints up to 4 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053HyperlipemiaNCT06229548CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.39
已完成
1 期
A Study of Safety, Tolerability, and Pharmacokinetics of Single Doses of PHP-303 in Healthy SubjectsHealthy VolunteerNCT03627845pH Pharma49
Unknown
1 期
A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APBContact DermatitisNCT04853823Hapten Sciences, Inc.32
已完成
1 期
A Phase I, Single-Center Study of PDC-APB in Healthy VolunteersContact DermatitisNCT02700373Hapten Sciences, Inc.40
已完成
1 期
A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy ParticipantsAlzheimer DiseaseNCT06406348AbbVie53